@MkangoResources is due to complete its bankable feasibility studies for each of its rare earths mine in Malawi (Songwe Hill), and its separation plant in Poland, by the end of next month.
Details have been scarce, but #MKA has indicated the intended output of the...
2/8
...mine and separation plant - which is more than double that of the output suggested in the 2015 pre-feasibility study.
Presumably with a little guidance from #MKA mgmt, @MkangoResources' broker provided some very basic headline numbers of how the integrated operations...
3/8
...may turn out.
The ARC analyst has used a basket sales price of $42/kg. In the 2015 PFS, #MKA had used a basket price of $59.8/kg.
Given the very powerful moves over the past 20 months of the key 'magnet rare earths' (neodymium, praseodymium, terbium, dysprosium)...
4/8
...which make up the large majority of the basket price at #MKA's Songwe Hill, I decided to run a quick exercise using current REE spot prices, provided by Kitco.
Needless to say, @MkangoResources will not be using these ridiculously elevated...
@PetraDiamondsIR#PDL is now at 96p / £186m and threatening to break out. It's in touching distance of the post-restructuring, intra-day high of 97.5p, with blue skies above.
Interim results are due out next Wednesday.
A basic summary of the investment case ⬇️
1/25
#PDL is a diamond miner, with interests in 4 mines:
3 underground mines in South Africa (all 74% owned), namely: Cullinan, Finsch, and Koffiefontein;
1 open pit mine (75% owned) in Tanzania, named Williamson.
The mines were all acquired from @DeBeers between 2007-11.
2/25
The mines had all suffered from underinvestment when owned by @DeBeers. As such, between 2006 and 2019, #PDL invested approximately $1.6bn in improving the operational efficiencies of the mines and in extending their lives.
The contrasting opinions on @avacta's valuation on FinTwit is fascinating.
Those who think #AVCT is overvalued, just can't seem to get their heads around the possibility that a £250m British biotech could be on the cusp of revolutionizing cancer treatment.
For each of its past two FYs, #APTA has generated no more than £1m in revenue.
The Affimer platform is a next generation antibody mimetic platform. It was "engineered to overcome many of the problems associated with aptamers or with antibodies". ⬇️
To my knowledge, #APTA (or its partners) has not put in place manufacturing capacity of 30+ million per month to sell propreitary, Aptamer-based SARS-CoV-2 LFTs.
The air of failure surrounding #AVCT this week on Twitter and the bulletin boards - largely from non- and ex-holders - is truly mystifying.
We will have a very good idea of whether the pre CISION platform is working, in the coming few weeks…
1/
@PapaDoc3333@TrivChannel …either from dose escalation in AVA6000 P1a; or from candidate selection for AVA3996.
One vital, silver lining of #AVCT’s RNS on Monday:
Alastair Smith has made it very clear that he is a man of integrity. He could have allowed M19 to continue selling MeduFlow in the EU, 2/n
@PapaDoc3333@TrivChannel … and continue with their application to the FDA for EUA (home-use) in the US - whilst improving the strip simultaneously in the background.
All other LFT providers are doing this, after all.
On Monday, #AVCT announced that it had received FDA approval for its Investigational New Drug ('IND') application, to expand its Phase I clinical trial for AVA6000, into trial sites in the US.
The timing of the submission and the length of review are critical.
2/25
The FDA has a 30-day review and turnaround time. Given #AVCT announced the approval this Monday, owing to LSE disclosure laws we must assume it received the approval sometime between Friday and Sunday.
Give a few days for post / admin / comms delays, and we can assume...